Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) has several different actions in the nervous system, including neuroprotective effects. In the present study, we investigated the effects of different doses of PACAP on the functional and morphological outcome in a rat model of Parkinson's disease. Rats were given unilateral injections of 6-hydroxydopamine (6-OHDA) into the substantia nigra. PACAP-treated animals received 1, 0.1 or 0.01 μg PACAP as a pretreatment. Control animals without PACAP treatment displayed severe hypokinesia at 1 and 10 days post-lesion when compared to normal animals or those receiving saline only. PACAP treatment resulted in less severe acute hypokinesia, and complete recovery by 10 days. Asymmetrical signs were observed in all lesioned animals 1 day post-lesion. PACAP-treated animals, however, showed better recovery as they ceased to display asymmetrical signs 10 days later and showed markedly less apomorphine-induced rotations. Best behavioral outcome was observed in animals treated with 0.1 μg PACAP. Tyrosine-hydroxylase (TH) immunohistochemistry revealed increased number of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area in all PACAP-treated rats in contrast to the severe cell loss in control animals. These results indicate that PACAP may be a promising therapeutic agent in Parkinson's disease.

Original languageEnglish
Pages (from-to)85-94
Number of pages10
JournalRegulatory Peptides
Volume123
Issue number1-3 SPEC. ISS.
DOIs
Publication statusPublished - Dec 15 2004

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Oxidopamine
Substantia Nigra
Rats
Animals
Hypokinesia
Parkinson Disease
Recovery
Ventral Tegmental Area
Apomorphine
Dopaminergic Neurons
Tyrosine 3-Monooxygenase
Neurology
Neuroprotective Agents
Nervous System
Neurons
Therapeutics
Immunohistochemistry

Keywords

  • Neuroprotection
  • Parkinson's disease
  • Tyrosine-hydroxylase
  • Ventral tegmental area

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Neuroscience(all)

Cite this

Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats. / Reglodi, D.; Tamás, A.; Lubics, A.; Szalontay, Luca; Lengvári, I.

In: Regulatory Peptides, Vol. 123, No. 1-3 SPEC. ISS., 15.12.2004, p. 85-94.

Research output: Contribution to journalArticle

@article{15cc6e32805343a7b7745a87ee94fe72,
title = "Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats",
abstract = "Pituitary adenylate cyclase activating polypeptide (PACAP) has several different actions in the nervous system, including neuroprotective effects. In the present study, we investigated the effects of different doses of PACAP on the functional and morphological outcome in a rat model of Parkinson's disease. Rats were given unilateral injections of 6-hydroxydopamine (6-OHDA) into the substantia nigra. PACAP-treated animals received 1, 0.1 or 0.01 μg PACAP as a pretreatment. Control animals without PACAP treatment displayed severe hypokinesia at 1 and 10 days post-lesion when compared to normal animals or those receiving saline only. PACAP treatment resulted in less severe acute hypokinesia, and complete recovery by 10 days. Asymmetrical signs were observed in all lesioned animals 1 day post-lesion. PACAP-treated animals, however, showed better recovery as they ceased to display asymmetrical signs 10 days later and showed markedly less apomorphine-induced rotations. Best behavioral outcome was observed in animals treated with 0.1 μg PACAP. Tyrosine-hydroxylase (TH) immunohistochemistry revealed increased number of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area in all PACAP-treated rats in contrast to the severe cell loss in control animals. These results indicate that PACAP may be a promising therapeutic agent in Parkinson's disease.",
keywords = "Neuroprotection, Parkinson's disease, Tyrosine-hydroxylase, Ventral tegmental area",
author = "D. Reglodi and A. Tam{\'a}s and A. Lubics and Luca Szalontay and I. Lengv{\'a}ri",
year = "2004",
month = "12",
day = "15",
doi = "10.1016/j.regpep.2004.05.016",
language = "English",
volume = "123",
pages = "85--94",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "1-3 SPEC. ISS.",

}

TY - JOUR

T1 - Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats

AU - Reglodi, D.

AU - Tamás, A.

AU - Lubics, A.

AU - Szalontay, Luca

AU - Lengvári, I.

PY - 2004/12/15

Y1 - 2004/12/15

N2 - Pituitary adenylate cyclase activating polypeptide (PACAP) has several different actions in the nervous system, including neuroprotective effects. In the present study, we investigated the effects of different doses of PACAP on the functional and morphological outcome in a rat model of Parkinson's disease. Rats were given unilateral injections of 6-hydroxydopamine (6-OHDA) into the substantia nigra. PACAP-treated animals received 1, 0.1 or 0.01 μg PACAP as a pretreatment. Control animals without PACAP treatment displayed severe hypokinesia at 1 and 10 days post-lesion when compared to normal animals or those receiving saline only. PACAP treatment resulted in less severe acute hypokinesia, and complete recovery by 10 days. Asymmetrical signs were observed in all lesioned animals 1 day post-lesion. PACAP-treated animals, however, showed better recovery as they ceased to display asymmetrical signs 10 days later and showed markedly less apomorphine-induced rotations. Best behavioral outcome was observed in animals treated with 0.1 μg PACAP. Tyrosine-hydroxylase (TH) immunohistochemistry revealed increased number of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area in all PACAP-treated rats in contrast to the severe cell loss in control animals. These results indicate that PACAP may be a promising therapeutic agent in Parkinson's disease.

AB - Pituitary adenylate cyclase activating polypeptide (PACAP) has several different actions in the nervous system, including neuroprotective effects. In the present study, we investigated the effects of different doses of PACAP on the functional and morphological outcome in a rat model of Parkinson's disease. Rats were given unilateral injections of 6-hydroxydopamine (6-OHDA) into the substantia nigra. PACAP-treated animals received 1, 0.1 or 0.01 μg PACAP as a pretreatment. Control animals without PACAP treatment displayed severe hypokinesia at 1 and 10 days post-lesion when compared to normal animals or those receiving saline only. PACAP treatment resulted in less severe acute hypokinesia, and complete recovery by 10 days. Asymmetrical signs were observed in all lesioned animals 1 day post-lesion. PACAP-treated animals, however, showed better recovery as they ceased to display asymmetrical signs 10 days later and showed markedly less apomorphine-induced rotations. Best behavioral outcome was observed in animals treated with 0.1 μg PACAP. Tyrosine-hydroxylase (TH) immunohistochemistry revealed increased number of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area in all PACAP-treated rats in contrast to the severe cell loss in control animals. These results indicate that PACAP may be a promising therapeutic agent in Parkinson's disease.

KW - Neuroprotection

KW - Parkinson's disease

KW - Tyrosine-hydroxylase

KW - Ventral tegmental area

UR - http://www.scopus.com/inward/record.url?scp=7044227726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044227726&partnerID=8YFLogxK

U2 - 10.1016/j.regpep.2004.05.016

DO - 10.1016/j.regpep.2004.05.016

M3 - Article

C2 - 15518897

AN - SCOPUS:7044227726

VL - 123

SP - 85

EP - 94

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 1-3 SPEC. ISS.

ER -